Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced or Metastatic Solid Malignancies 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Adenocarcinoma 1

Interventions

toripalimab 6Injections 4tislelizumab 3sintilimab 3pembrolizumab 3cediranib 3glumetinib 2apatinib 2PM 01183 2Midazolam 2Irinotecan 2Gemcitabine 2Drug Therapy 2Digoxin 2Bupropion 2talazoparib 1spartalizumab 1sonidegib 1sitravatinib 1serabelisib 1sapanisertib 1rucaparib 1repaglinide 1penpulimab 1palbociclib 1lenvatinib 1fluzoparib 1erdafitinib 1entrectinib 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumor × sitravatinib × Clear all
NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡